Mark Kerr Acquires 231,453 Shares of Cryosite Limited (ASX:CTE) Stock

Cryosite Limited (ASX:CTE) insider Mark Kerr acquired 231,453 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average cost of A$0.80 ($0.50) per share, for a total transaction of A$185,162.40 ($116,454.34).

Cryosite Price Performance

The company has a market cap of $36.36 million, a PE ratio of 19.76 and a beta of 0.40. The company has a debt-to-equity ratio of 168.74, a current ratio of 1.94 and a quick ratio of 1.76.

About Cryosite

Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological, as well as logistics services to the clinical trials, research, and pharmaceutical industries.